Prognostic Value of Circulating Tumour DNA in Patients Undergoing Curative Resection for Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Jun 10

PMID 27280632

Citations 83

Authors

Naoto Hadano

Yoshiaki Murakami

Kenichiro Uemura

Yasusi Hashimoto

Naru Kondo

Naoya Nakagawa

Taijiro Sueda

Eiso Hiyama

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage, leading to a poor prognosis. Therefore, interest in the development of non-invasive biomarkers for prognostic prediction has grown rapidly. Here, we assessed the clinical implications of v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated circulating tumour DNA (ctDNA) as a useful surrogate biomarker in patients with resectable PDAC.

Methods: We used droplet digital polymerase chain reaction to detect rare mutant tumour-derived KRAS genes in plasma cell-free DNA (cfDNA) as ctDNA. Samples were collected from 105 patients who underwent pancreatoduodenectomy for PDAC at a single institution. Overall survival (OS) was analysed according to the presence of ctDNA.

Results: Among the 105 cases, ctDNA was detected in 33 (31%) plasma samples. The median OS durations were 13.6 months for patients with ctDNA (ctDNA+) and 27.6 months for patients without ctDNA. Patients who were ctDNA+ had a significantly poorer prognosis with respect to OS (P<0.0001).

Conclusions: Our findings suggested that the presence of ctDNA in plasma samples could be an important and powerful predictor of poor survival in patients with PDAC. Accordingly, ctDNA detection might be a promising approach with respect to PDAC treatment.

Citing Articles

Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study.

Leiting J, Alva-Ruiz R, Yonkus J, Abdelrahman A, Lynch I, Carlson D Ann Surg Oncol. 2025; .

PMID: 40067610 DOI: 10.1245/s10434-025-17036-y.

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.

Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T Int J Clin Oncol. 2025; .

PMID: 39920551 DOI: 10.1007/s10147-024-02683-0.

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.

Maulat C, Canivet C, Cabarrou B, Pradines A, Selves J, Casanova A Sci Rep. 2024; 14(1):27296.

PMID: 39516243 PMC: 11549393. DOI: 10.1038/s41598-024-76903-y.

Prognostic Role of Specific Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer.

Halkova T, Bunganic B, Traboulsi E, Minarik M, Zavoral M, Benesova L Genes (Basel). 2024; 15(10).

PMID: 39457426 PMC: 11507146. DOI: 10.3390/genes15101302.

Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma-A New Tool for Molecular Profiling of Mutations in Tumor and Plasma Samples.

Bravo A, Morao B, Luz A, Dourado R, Oliveira B, Guedes A Cancers (Basel). 2024; 16(20).

PMID: 39456638 PMC: 11506488. DOI: 10.3390/cancers16203544.

References

Kato S, Janku F . Cell-free DNA as a novel marker in cancer therapy. Biomark Med. 2015; 9(7):703-12. DOI: 10.2217/bmm.15.38. View

Gao S, Zheng C, Chang G, Liu W, Kou X, Tan K . Unique features of mutations revealed by sequentially reprogrammed induced pluripotent stem cells. Nat Commun. 2015; 6:6318. DOI: 10.1038/ncomms7318. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

Ballehaninna U, Chamberlain R . The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012; 3(2):105-19. PMC: 3397644. DOI: 10.3978/j.issn.2078-6891.2011.021. View

Hindson C, Chevillet J, Briggs H, Gallichotte E, Ruf I, Hindson B . Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013; 10(10):1003-5. PMC: 4118677. DOI: 10.1038/nmeth.2633. View

Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N . Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015; 5:18425. PMC: 4680882. DOI: 10.1038/srep18425. View

Hindson B, Ness K, Masquelier D, Belgrader P, Heredia N, Makarewicz A . High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83(22):8604-10. PMC: 3216358. DOI: 10.1021/ac202028g. View

Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T . Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1996; 110(1):227-31. DOI: 10.1053/gast.1996.v110.pm8536861. View

10.

Diaz Jr L, Bardelli A . Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6):579-86. PMC: 4820760. DOI: 10.1200/JCO.2012.45.2011. View

11.

Tada M, Omata M, OHTO M . Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology. 1991; 100(1):233-8. DOI: 10.1016/0016-5085(91)90606-l. View

12.

Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger R, Schwab G . High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer. 1989; 43(6):1037-41. DOI: 10.1002/ijc.2910430614. View

13.

Mead R, Duku M, Bhandari P, Cree I . Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011; 105(2):239-45. PMC: 3142810. DOI: 10.1038/bjc.2011.230. View

14.

Sun B, Tao L, Zheng Y . Simultaneous quantification of alternatively spliced transcripts in a single droplet digital PCR reaction. Biotechniques. 2014; 56(6):319-25. DOI: 10.2144/000114179. View

15.

Gormally E, Caboux E, Vineis P, Hainaut P . Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007; 635(2-3):105-117. DOI: 10.1016/j.mrrev.2006.11.002. View

16.

Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S . K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000; 89(6):469-74. DOI: 10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l. View

17.

Kamat A, Baldwin M, Urbauer D, Dang D, Han L, Godwin A . Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010; 116(8):1918-25. PMC: 2854845. DOI: 10.1002/cncr.24997. View

18.

Hashad D, Sorour A, Ghazal A, Talaat I . Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012; 26(6):467-72. PMC: 6807470. DOI: 10.1002/jcla.21548. View

19.

Biankin A, Waddell N, Kassahn K, Gingras M, Muthuswamy L, Johns A . Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491(7424):399-405. PMC: 3530898. DOI: 10.1038/nature11547. View

20.

Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H . Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 2012; 48(5):640-6. DOI: 10.1007/s00535-012-0664-2. View